Skip to content

Effect of Transcutaneous Acupoint Electrical Stimulation on Postoperative Spontaneous Voiding for Laparoscopic Patients

Effect of Transcutaneous Acupoint Electrical Stimulation on Postoperative Spontaneous Voiding for Laparoscopic Cholecystectomy Patients:A Randomized Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03631160
Enrollment
1948
Registered
2018-08-15
Start date
2018-08-20
Completion date
2020-08-24
Last updated
2021-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Voiding Disorders

Keywords

Laparoscopic Cholecystectomy, Transcutaneous Acupoint Electrical Stimulation, Postoperative spontaneous voiding, Postoperative Dysuria

Brief summary

1. Title: Effect of Transcutaneous Acupoint Electrical Stimulation on postoperative spontaneous voiding for Laparoscopic Cholecystectomy patients:A Randomized Clinical Trial 2. Research center: Multicenter 3. Design of the research: A randomized, double-blind and parallel controlled study 4. Object of the research: Patients (40≤age\<75 years)planing to elective laparoscopic cholecystectomy under general anesthesia without preoperative placement of catheter. 5. Sample size of the research: A total of 1,200 patients,600 cases in each group 6. Interventions: The acupuncture points for Transcutaneous Acupoint Electrical Stimulation(TAES) are Zhongji ( CV3),Guanyuan ( CV4),Sanyinjiao ( SP6) and Ciliao ( BL32) points . In treatment group patients are treated with low-frequency pulse electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) at bilateral of SP6 and BL 32 points during the operation,and treated with a similar method at CV6 and CV4 acupoints for 45 minutes in postanesthesia Care Unit. Each devic is connected and maintained after Deqi. Participants in the control group received nonacupoints (located 1 inch beside acupoints) and avoided manual stimulation and no Deqi without actual current output. 7. Aim of the research: Evaluate the effect of TAES on the postoperative spontaneous voiding in patients for Laparoscopic Cholecystectomy (LC ). 8. Outcome:Primary outcomes: The time of the first spontaneous voiding after surgery . Secondary outcomes: symptoms of postoperative voiding, the incidence of Postoperative dysuria,postoperative catheterization rate, catheterization time, incidence of related complications,as well as the effects on postoperative NRS pain and sleep quality scores etc. 9. The estimated duration of the study:2 years.

Detailed description

This study is a large sample, randomized, double-blinded, placebo-controlled and long-term follow-up design. In this study, bilateralZhongji ( CV3),Guanyuan ( CV4),Sanyinjiao ( SP6) and Ciliao ( BL32) points were selected for perioperative TAES treatment, accompanied with evaluating the postoperative spontaneous voiding, the incidence of Postoperative dysuria,postoperative catheterization rate, as well as the effects on postoperative NRS pain and sleep quality scores . To clarify the effect of TAES on the postoperative spontaneous voiding in patients for laparoscopic surgery is of great significance to the clinical applications and popularization of traditional acupuncture treatment perioperatively across the world.

Interventions

DEVICETAES treatmen

In the acupoints group patients are treated with low-frequency pulse electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) at SP6 and BL 32 points during the operation in the operating room ,and at CV3 and CV4 acupoints for 45 minutes in postanesthesia Care Unit. After Deqi, electroacupuncture stimulation apparatus is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \ 30 milliamp (mA) (gradually increase to the patient's maximum tolerance) and maintained until the end of treatment.

DEVICESham TAES treatmen

Participants in the acupoints group receive shallow acupointing at SP6, BL 32 ,CV3 and CV4 (nonacupoints located 1 inch beside acupoints, about 20mm).Specifically, the acupoint is shamed without manual stimulation and Deqi and the stimulation apparatus is inefficiency without actual current output .

Sponsors

Tianjin First Central Hospital
CollaboratorOTHER
Tianjin Beichen Hospital
CollaboratorUNKNOWN
Anyang People's Hospital
CollaboratorUNKNOWN
Tianjin Nankai Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

Subjects who have signed informed consent were assigned to either TEAS group or control group on the basis of digital random numbers generated by SPSS.23.0 software. The acupuncturist(Z.-Y.) was informed of the randomization allocation each subject by a concealed envelope, just before the onset of TEAS. And during the treatment, the screen of all acupuncture treatment instruments was covered from to ensure the anesthesiologist and surgeon blinded. The acupuncturist, statistician, and data collectors work independently and only perform assigned tasks, besides after the agreement is initiated, all researchers will not have any private communication with the study.

Intervention model description

patients undergoing elective laparoscopy cholecystectomy surgery were recruited and allocated into TEAS(transcutaneous electrical acupoint stimulation)group or control group

Eligibility

Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Age ≥ 40 years old and \< 75 years old, gender and nationality are not limited; 2. Patients undergoing elective laparoscopic cholecystectomy under general anesthesia 3. agree to participate in this study and sign the informed consent;

Exclusion criteria

1. Refused to participate in this study; 2. laparotomy or preventive indwelling catheter; 3. There are obvious symptoms of urinary difficulty caused by various causes recently; 4. Patients who are have treatment taboo with skin injury or insensitivity to acupoint stimulation. 5. Critical condition (preoperative ASA grade ≥ IV grade); severe renal impairment (need to undergo renal replacement therapy); severe liver and kidney dysfunction (Child-Pugh grade C); 6. There are other circumstances where it is not appropriate to participate in this study

Design outcomes

Primary

MeasureTime frameDescription
The first spontaneous voiding after surgeryan average of 1 yearRecord the time from the end of the procedure to the patient's first spontaneous postoperatively, and record the amount of urine and discomfort

Secondary

MeasureTime frameDescription
postoperative catheterization rate12 monthsThe incidence of catheterization in patients who were unable to urinate for a long time after surgery
Incidence Urinary tract complications after surgery (including re-hospitalization)an average of 1 yearUrinary retention, urinary incontinence, hematuria, urinary tract infection, etc.
NRS pain scores12 monthsNRS method is used to evaluate the pain scores of patients (0 points to complete Painless, 10 points to the maximum pain that can be tolerated) The NRS method was used to evaluate the pain scores of patients at resting state and activity (cough) 6-8 hours after operation.
symptoms of postoperative voidingan average of 1 yearThe number of urination, total urine output and possible urinary discomfort symptoms during the perioperative period
The effects on postoperative sleep quality scores12 monthsUsing the NRS method (0 for the best quality of sleep and 10 for the worst quality of sleep)
Length of stay in hospital after surgeryan average of 1 yearThe hospitalization time from the patient's surgery to the time of discharge (excluding re-hospitalization)
Anxiety and depression assessmentan average of 1 yearUsing Hospital Anxiety and Depression Scale (HADS) to evaluate perioperative anxiety and depression of patients.HADS includes two scales of anxiety and depression, of which 0-7 is negative, 8-10 is mild, 11-14 is moderate, and 15-21 is severe.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026